CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes
Severe acute respiratory syndrome coronavirus 2–neutralizing antibodies primarily target the spike receptor binding domain (RBD). However, B cell antigen receptors (BCRs) on RBD-binding memory B (B mem ) cells have variation in the neutralizing activities. Here, by combining single B mem cell profil...
Saved in:
| Published in | Science advances Vol. 9; no. 24; p. eadf0661 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Association for the Advancement of Science
16.06.2023
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Severe acute respiratory syndrome coronavirus 2–neutralizing antibodies primarily target the spike receptor binding domain (RBD). However, B cell antigen receptors (BCRs) on RBD-binding memory B (B
mem
) cells have variation in the neutralizing activities. Here, by combining single B
mem
cell profiling with antibody functional assessment, we dissected the phenotype of B
mem
cell harboring the potently neutralizing antibodies in coronavirus disease 2019 (COVID-19)–convalescent individuals. The neutralizing subset was marked by an elevated CD62L expression and characterized by distinct epitope preference and usage of convergent V
H
(variable region of immunoglobulin heavy chain) genes, accounting for the neutralizing activities. Concordantly, the correlation was observed between neutralizing antibody titers in blood and CD62L
+
subset, despite the equivalent RBD binding of CD62L
+
and CD62L
−
subset. Furthermore, the kinetics of CD62L
+
subset differed between the patients who recovered from different COVID-19 severities. Our B
mem
cell profiling reveals the unique phenotype of B
mem
cell subset that harbors potently neutralizing BCRs, advancing our understanding of humoral protection.
Phenotypic profiling of SARS-CoV-2 memory B-cells reveals neutralizing subset. |
|---|---|
| AbstractList | Severe acute respiratory syndrome coronavirus 2–neutralizing antibodies primarily target the spike receptor binding domain (RBD). However, B cell antigen receptors (BCRs) on RBD-binding memory B (B
mem
) cells have variation in the neutralizing activities. Here, by combining single B
mem
cell profiling with antibody functional assessment, we dissected the phenotype of B
mem
cell harboring the potently neutralizing antibodies in coronavirus disease 2019 (COVID-19)–convalescent individuals. The neutralizing subset was marked by an elevated CD62L expression and characterized by distinct epitope preference and usage of convergent V
H
(variable region of immunoglobulin heavy chain) genes, accounting for the neutralizing activities. Concordantly, the correlation was observed between neutralizing antibody titers in blood and CD62L
+
subset, despite the equivalent RBD binding of CD62L
+
and CD62L
−
subset. Furthermore, the kinetics of CD62L
+
subset differed between the patients who recovered from different COVID-19 severities. Our B
mem
cell profiling reveals the unique phenotype of B
mem
cell subset that harbors potently neutralizing BCRs, advancing our understanding of humoral protection.
Phenotypic profiling of SARS-CoV-2 memory B-cells reveals neutralizing subset. Severe acute respiratory syndrome coronavirus 2-neutralizing antibodies primarily target the spike receptor binding domain (RBD). However, B cell antigen receptors (BCRs) on RBD-binding memory B (Bmem) cells have variation in the neutralizing activities. Here, by combining single Bmem cell profiling with antibody functional assessment, we dissected the phenotype of Bmem cell harboring the potently neutralizing antibodies in coronavirus disease 2019 (COVID-19)-convalescent individuals. The neutralizing subset was marked by an elevated CD62L expression and characterized by distinct epitope preference and usage of convergent VH (variable region of immunoglobulin heavy chain) genes, accounting for the neutralizing activities. Concordantly, the correlation was observed between neutralizing antibody titers in blood and CD62L+ subset, despite the equivalent RBD binding of CD62L+ and CD62L- subset. Furthermore, the kinetics of CD62L+ subset differed between the patients who recovered from different COVID-19 severities. Our Bmem cell profiling reveals the unique phenotype of Bmem cell subset that harbors potently neutralizing BCRs, advancing our understanding of humoral protection.Severe acute respiratory syndrome coronavirus 2-neutralizing antibodies primarily target the spike receptor binding domain (RBD). However, B cell antigen receptors (BCRs) on RBD-binding memory B (Bmem) cells have variation in the neutralizing activities. Here, by combining single Bmem cell profiling with antibody functional assessment, we dissected the phenotype of Bmem cell harboring the potently neutralizing antibodies in coronavirus disease 2019 (COVID-19)-convalescent individuals. The neutralizing subset was marked by an elevated CD62L expression and characterized by distinct epitope preference and usage of convergent VH (variable region of immunoglobulin heavy chain) genes, accounting for the neutralizing activities. Concordantly, the correlation was observed between neutralizing antibody titers in blood and CD62L+ subset, despite the equivalent RBD binding of CD62L+ and CD62L- subset. Furthermore, the kinetics of CD62L+ subset differed between the patients who recovered from different COVID-19 severities. Our Bmem cell profiling reveals the unique phenotype of Bmem cell subset that harbors potently neutralizing BCRs, advancing our understanding of humoral protection. Severe acute respiratory syndrome coronavirus 2-neutralizing antibodies primarily target the spike receptor binding domain (RBD). However, B cell antigen receptors (BCRs) on RBD-binding memory B (B ) cells have variation in the neutralizing activities. Here, by combining single B cell profiling with antibody functional assessment, we dissected the phenotype of B cell harboring the potently neutralizing antibodies in coronavirus disease 2019 (COVID-19)-convalescent individuals. The neutralizing subset was marked by an elevated CD62L expression and characterized by distinct epitope preference and usage of convergent V (variable region of immunoglobulin heavy chain) genes, accounting for the neutralizing activities. Concordantly, the correlation was observed between neutralizing antibody titers in blood and CD62L subset, despite the equivalent RBD binding of CD62L and CD62L subset. Furthermore, the kinetics of CD62L subset differed between the patients who recovered from different COVID-19 severities. Our B cell profiling reveals the unique phenotype of B cell subset that harbors potently neutralizing BCRs, advancing our understanding of humoral protection. |
| Author | Inoue, Takeshi Shinkai, Masaharu Onodera, Taishi Nagakura, Takaki Adachi, Yu Omoto, Shinnya Moriyama, Saya Tonouchi, Keisuke Isogawa, Masanori Kotaki, Ryutaro Yoshikawa, Mai Fukushi, Shuetsu Matsumura, Takayuki Nishiyama, Ayae Takano, Tomohiro Kurosaki, Tomohiro Nakagawa, Takayuki Terahara, Kazutaka Sax, Nicolas Shinnakasu, Ryo Terooatea, Tommy Takahashi, Yoshimasa Yamashita, Kazuo Sun, Lin Sato, Takashi |
| Author_xml | – sequence: 1 givenname: Taishi orcidid: 0000-0002-7079-3339 surname: Onodera fullname: Onodera, Taishi organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 2 givenname: Nicolas orcidid: 0000-0003-3241-4737 surname: Sax fullname: Sax, Nicolas organization: KOTAI Biotechnologies Inc., Osaka, Japan – sequence: 3 givenname: Takashi orcidid: 0000-0002-2676-3781 surname: Sato fullname: Sato, Takashi organization: Tokyo Shinagawa Hospital, Tokyo, Japan – sequence: 4 givenname: Yu orcidid: 0000-0002-8573-987X surname: Adachi fullname: Adachi, Yu organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 5 givenname: Ryutaro orcidid: 0000-0001-7965-1671 surname: Kotaki fullname: Kotaki, Ryutaro organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 6 givenname: Takeshi orcidid: 0000-0002-9972-6105 surname: Inoue fullname: Inoue, Takeshi organization: Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan – sequence: 7 givenname: Ryo surname: Shinnakasu fullname: Shinnakasu, Ryo organization: Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan – sequence: 8 givenname: Takayuki orcidid: 0000-0002-6247-3191 surname: Nakagawa fullname: Nakagawa, Takayuki organization: Shionogi & Co. Ltd., Osaka, Japan – sequence: 9 givenname: Shuetsu surname: Fukushi fullname: Fukushi, Shuetsu organization: Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 10 givenname: Tommy orcidid: 0000-0001-9248-3342 surname: Terooatea fullname: Terooatea, Tommy organization: KOTAI Biotechnologies Inc., Osaka, Japan – sequence: 11 givenname: Mai surname: Yoshikawa fullname: Yoshikawa, Mai organization: Shionogi & Co. Ltd., Osaka, Japan – sequence: 12 givenname: Keisuke surname: Tonouchi fullname: Tonouchi, Keisuke organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan., Department of Life Science and Medical Bioscience, Waseda University, Tokyo, Japan – sequence: 13 givenname: Takaki orcidid: 0000-0002-1204-4815 surname: Nagakura fullname: Nagakura, Takaki organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan., Laboratory of Viral Infection, Ōmura Satoshi Memorial Institute Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan – sequence: 14 givenname: Saya orcidid: 0000-0003-2057-9198 surname: Moriyama fullname: Moriyama, Saya organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 15 givenname: Takayuki orcidid: 0000-0003-1760-3484 surname: Matsumura fullname: Matsumura, Takayuki organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 16 givenname: Masanori orcidid: 0000-0001-8730-4303 surname: Isogawa fullname: Isogawa, Masanori organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 17 givenname: Kazutaka orcidid: 0000-0001-9876-4356 surname: Terahara fullname: Terahara, Kazutaka organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 18 givenname: Tomohiro orcidid: 0000-0003-4267-1147 surname: Takano fullname: Takano, Tomohiro organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 19 givenname: Lin surname: Sun fullname: Sun, Lin organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 20 givenname: Ayae surname: Nishiyama fullname: Nishiyama, Ayae organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 21 givenname: Shinnya orcidid: 0000-0002-2730-3912 surname: Omoto fullname: Omoto, Shinnya organization: Shionogi & Co. Ltd., Osaka, Japan – sequence: 22 givenname: Masaharu orcidid: 0000-0002-4012-2518 surname: Shinkai fullname: Shinkai, Masaharu organization: Tokyo Shinagawa Hospital, Tokyo, Japan – sequence: 23 givenname: Tomohiro orcidid: 0000-0002-6352-304X surname: Kurosaki fullname: Kurosaki, Tomohiro organization: Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan., Center for Infectious Diseases Education and Research, Osaka University, Osaka, Japan – sequence: 24 givenname: Kazuo orcidid: 0000-0002-7825-4719 surname: Yamashita fullname: Yamashita, Kazuo organization: KOTAI Biotechnologies Inc., Osaka, Japan – sequence: 25 givenname: Yoshimasa orcidid: 0000-0001-6342-4087 surname: Takahashi fullname: Takahashi, Yoshimasa organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37315144$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1UUtP3DAQtipQocCVI_Kxl2z9ipOcKrrQh7QSUnlcjdcZg9vEDnaylP76erVbRCtxmtHM933z-N6hHR88IHRMyYxSJj8k43S7munWEinpG7TPeFUWrBT1zot8Dx2l9IMQQoWUJW3eoj1ecVpSIfbR7fxMsgWGX0OElFzwuNfxZ8KXp98vi3m4KRjuoQ_xCX_CBroOp2mZYMSPbrzHmWMhgjeAbYjYwzRG3bnfzt9hGNwYBkiHaNfqLsHRNh6g68_nV_OvxeLiy7f56aIwvKFjIQitTSVKoa0Vsm2M4aZp6iZXKtIYroXkICwvq2VjNFDWSgJWWru0tOWS8QP0caM7TMseWgN-vYsaossHPamgnfq34929ugsrRQmTsmI0K7zfKsTwMEEaVe_S-mbtIUxJsZpJRmXF6ww9eTnsecrfv2bAbAMwMaSU3_QMoUStvVMb79TWu0wQ_xGMG_WYDcnLuu412h-x4KDz |
| CitedBy_id | crossref_primary_10_1093_jleuko_qiae228 crossref_primary_10_3389_fimmu_2025_1550279 crossref_primary_10_3390_microorganisms12112272 crossref_primary_10_1126_scitranslmed_adp9927 crossref_primary_10_1016_j_jaci_2025_02_026 |
| Cites_doi | 10.1126/science.abc7520 10.1016/j.cell.2019.03.048 10.1038/nri3802 10.1038/s41586-022-04980-y 10.1038/s41586-020-2456-9 10.1016/j.immuni.2015.10.015 10.1126/science.abd2321 10.1016/j.immuni.2019.06.024 10.1038/s41586-020-2852-1 10.1038/s41586-021-03207-w 10.1126/sciimmunol.aai8153 10.1038/s41590-021-01078-x 10.1016/j.cell.2021.01.007 10.1016/j.immuni.2020.06.013 10.1016/j.immuni.2021.05.001 10.1093/bioinformatics/btv359 10.1016/j.cell.2020.09.037 10.1016/j.cell.2021.02.032 10.1126/science.abm0829 10.1016/j.chom.2021.02.003 10.1016/j.cell.2021.04.032 10.1016/j.immuni.2015.12.004 10.1016/j.cell.2020.11.029 10.1038/ni.3533 10.1016/j.jim.2007.09.017 10.1016/j.cell.2019.11.003 10.1038/s41579-021-00573-0 10.12688/f1000research.2-103.v1 10.1016/j.immuni.2015.10.021 10.1038/s41586-021-04385-3 10.1016/j.it.2022.03.005 10.1038/s41591-020-0913-5 10.1016/j.medj.2022.02.006 10.1016/j.immuni.2021.07.008 10.1111/cei.12795 10.1038/ni.1667 10.1038/s41591-021-01377-8 10.1093/cei/uxac114 10.1186/s13059-019-1874-1 10.1016/j.cell.2021.02.035 10.1016/j.immuni.2021.06.015 10.1016/j.celrep.2021.109823 10.1186/s12985-021-01490-7 10.1038/s41586-021-04060-7 10.1126/sciimmunol.abn8590 10.1016/j.immuni.2021.08.025 |
| ContentType | Journal Article |
| Copyright | Copyright © 2023 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY). 2023 The Authors |
| Copyright_xml | – notice: Copyright © 2023 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY). 2023 The Authors |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1126/sciadv.adf0661 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | Neutralizing memory B-cell subset to SARS-CoV-2 |
| EISSN | 2375-2548 |
| ExternalDocumentID | PMC10266721 37315144 10_1126_sciadv_adf0661 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: ; grantid: JP21fk0108534 – fundername: ; grantid: JP20fk0108534 – fundername: ; grantid: JP22gm1810004 – fundername: ; grantid: JP19fk0108104 – fundername: ; grantid: JP 22gm1810004 – fundername: ; grantid: JP22fk0108141 – fundername: ; grantid: JP20fk0108104 |
| GroupedDBID | 53G 5VS AAFWJ AAYXX ACGFS ADAXU ADBBV ADPDF AENVI AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BCGUY BCNDV BKF CITATION EBS FRP GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 OVD OVEED RHI RPM TEORI BBORY CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c391t-4018c7454aff46d9cc3c9989454709c3a463e4f357b9cae12d60ef6ffbf1d3623 |
| IEDL.DBID | M48 |
| ISSN | 2375-2548 |
| IngestDate | Thu Aug 21 18:37:19 EDT 2025 Fri Jul 11 08:38:48 EDT 2025 Thu Apr 03 07:01:01 EDT 2025 Thu Apr 24 22:59:57 EDT 2025 Tue Jul 01 03:11:50 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 24 |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c391t-4018c7454aff46d9cc3c9989454709c3a463e4f357b9cae12d60ef6ffbf1d3623 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-4012-2518 0000-0002-1204-4815 0000-0002-9972-6105 0000-0002-6247-3191 0000-0002-6352-304X 0000-0001-9876-4356 0000-0001-8730-4303 0000-0002-7079-3339 0000-0003-1760-3484 0000-0001-7965-1671 0000-0001-9248-3342 0000-0003-2057-9198 0000-0001-6342-4087 0000-0002-8573-987X 0000-0002-7825-4719 0000-0002-2676-3781 0000-0002-2730-3912 0000-0003-4267-1147 0000-0003-3241-4737 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1126/sciadv.adf0661 |
| PMID | 37315144 |
| PQID | 2826216738 |
| PQPubID | 23479 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10266721 proquest_miscellaneous_2826216738 pubmed_primary_37315144 crossref_primary_10_1126_sciadv_adf0661 crossref_citationtrail_10_1126_sciadv_adf0661 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-06-16 |
| PublicationDateYYYYMMDD | 2023-06-16 |
| PublicationDate_xml | – month: 06 year: 2023 text: 2023-06-16 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Science advances |
| PublicationTitleAlternate | Sci Adv |
| PublicationYear | 2023 |
| Publisher | American Association for the Advancement of Science |
| Publisher_xml | – name: American Association for the Advancement of Science |
| References | e_1_3_3_17_2 e_1_3_3_16_2 e_1_3_3_19_2 e_1_3_3_38_2 e_1_3_3_18_2 e_1_3_3_39_2 e_1_3_3_13_2 e_1_3_3_36_2 e_1_3_3_12_2 e_1_3_3_37_2 e_1_3_3_15_2 e_1_3_3_34_2 e_1_3_3_14_2 e_1_3_3_35_2 e_1_3_3_32_2 e_1_3_3_33_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_10_2 e_1_3_3_31_2 e_1_3_3_40_2 e_1_3_3_6_2 e_1_3_3_5_2 e_1_3_3_8_2 e_1_3_3_7_2 e_1_3_3_28_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_29_2 e_1_3_3_24_2 e_1_3_3_47_2 e_1_3_3_23_2 e_1_3_3_26_2 e_1_3_3_45_2 e_1_3_3_25_2 e_1_3_3_46_2 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_43_2 e_1_3_3_44_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_41_2 e_1_3_3_3_2 e_1_3_3_21_2 e_1_3_3_42_2 |
| References_xml | – ident: e_1_3_3_8_2 doi: 10.1126/science.abc7520 – ident: e_1_3_3_40_2 doi: 10.1016/j.cell.2019.03.048 – ident: e_1_3_3_2_2 doi: 10.1038/nri3802 – ident: e_1_3_3_36_2 doi: 10.1038/s41586-022-04980-y – ident: e_1_3_3_13_2 doi: 10.1038/s41586-020-2456-9 – ident: e_1_3_3_34_2 doi: 10.1016/j.immuni.2015.10.015 – ident: e_1_3_3_28_2 doi: 10.1126/science.abd2321 – ident: e_1_3_3_16_2 doi: 10.1016/j.immuni.2019.06.024 – ident: e_1_3_3_9_2 doi: 10.1038/s41586-020-2852-1 – ident: e_1_3_3_15_2 doi: 10.1038/s41586-021-03207-w – ident: e_1_3_3_27_2 doi: 10.1126/sciimmunol.aai8153 – ident: e_1_3_3_20_2 doi: 10.1038/s41590-021-01078-x – ident: e_1_3_3_5_2 doi: 10.1016/j.cell.2021.01.007 – ident: e_1_3_3_21_2 doi: 10.1016/j.immuni.2020.06.013 – ident: e_1_3_3_24_2 doi: 10.1016/j.immuni.2021.05.001 – ident: e_1_3_3_46_2 doi: 10.1093/bioinformatics/btv359 – ident: e_1_3_3_7_2 doi: 10.1016/j.cell.2020.09.037 – ident: e_1_3_3_12_2 doi: 10.1016/j.cell.2021.02.032 – ident: e_1_3_3_3_2 doi: 10.1126/science.abm0829 – ident: e_1_3_3_10_2 doi: 10.1016/j.chom.2021.02.003 – ident: e_1_3_3_22_2 doi: 10.1016/j.cell.2021.04.032 – ident: e_1_3_3_32_2 doi: 10.1016/j.immuni.2015.12.004 – ident: e_1_3_3_14_2 doi: 10.1016/j.cell.2020.11.029 – ident: e_1_3_3_17_2 doi: 10.1038/ni.3533 – ident: e_1_3_3_41_2 doi: 10.1016/j.jim.2007.09.017 – ident: e_1_3_3_23_2 doi: 10.1016/j.cell.2019.11.003 – ident: e_1_3_3_38_2 doi: 10.1038/s41579-021-00573-0 – ident: e_1_3_3_47_2 doi: 10.12688/f1000research.2-103.v1 – ident: e_1_3_3_35_2 doi: 10.1016/j.immuni.2015.10.021 – ident: e_1_3_3_37_2 doi: 10.1038/s41586-021-04385-3 – ident: e_1_3_3_19_2 doi: 10.1016/j.it.2022.03.005 – ident: e_1_3_3_39_2 doi: 10.1038/s41591-020-0913-5 – ident: e_1_3_3_44_2 doi: 10.1016/j.medj.2022.02.006 – ident: e_1_3_3_30_2 doi: 10.1016/j.immuni.2021.07.008 – ident: e_1_3_3_25_2 doi: 10.1111/cei.12795 – ident: e_1_3_3_33_2 doi: 10.1038/ni.1667 – ident: e_1_3_3_4_2 doi: 10.1038/s41591-021-01377-8 – ident: e_1_3_3_26_2 doi: 10.1093/cei/uxac114 – ident: e_1_3_3_45_2 doi: 10.1186/s13059-019-1874-1 – ident: e_1_3_3_6_2 doi: 10.1016/j.cell.2021.02.035 – ident: e_1_3_3_11_2 doi: 10.1016/j.immuni.2021.06.015 – ident: e_1_3_3_18_2 doi: 10.1016/j.celrep.2021.109823 – ident: e_1_3_3_43_2 doi: 10.1186/s12985-021-01490-7 – ident: e_1_3_3_29_2 doi: 10.1038/s41586-021-04060-7 – ident: e_1_3_3_31_2 doi: 10.1126/sciimmunol.abn8590 – ident: e_1_3_3_42_2 doi: 10.1016/j.immuni.2021.08.025 |
| SSID | ssj0001466519 |
| Score | 2.2708783 |
| Snippet | Severe acute respiratory syndrome coronavirus 2–neutralizing antibodies primarily target the spike receptor binding domain (RBD). However, B cell antigen... Severe acute respiratory syndrome coronavirus 2-neutralizing antibodies primarily target the spike receptor binding domain (RBD). However, B cell antigen... |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | eadf0661 |
| SubjectTerms | Antibodies, Neutralizing Antibodies, Viral B-Lymphocyte Subsets Biomedicine and Life Sciences Coronavirus COVID-19 Epitopes Humans Immunology L-Selectin Microbiology SARS-CoV-2 SciAdv r-articles |
| Title | CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37315144 https://www.proquest.com/docview/2826216738 https://pubmed.ncbi.nlm.nih.gov/PMC10266721 |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3Pb9MwFLbQduEysQFbYZuMhDQ4eIpjx4kPE9oKZUKDA12n3oLrHwKxpaVJp5a_fs-uV9oVJC65xIqi92K_73t6-T6EXhc6EwXjhhiZqWBhRqTkmgg4Ch3gCWAQYcr3izjv8U_9rP9n_ikGsP4rtfN-Ur3x9fH01-wdbPiTpR9glLk9VsZB_QQmtAlVKfduBp8j1A_9Fi5EFnw-UpZnBHhRETUc1x-xWqPWgOfD-cmlgtR5grYiksSn89Rvo0e22kHbca_W-E0UlH77FH1rvxfpBbbTOPRa4Rs1_lnj7unXLmkPr0iKb_zA7QyfYd_IxzWcJrbBvkeLRwsjEgz4Fld2Enojv6HkYTuC82Bk62eo1_lw2T4n0VmBaCZpA6SRFjrnGVfOcWGk1kxLL8We8TyRmikumOWOZflAamVpakRinXBu4KiBkseeo41qWNk9hKVLEqNpATAy4YzbgTI5TRNVcCO5VEkLkftYljrKjnv3i-sy0I9UlPPYlzH2LXS0WD-aC278c-Wr-9SUsCd8fFRlh5O6BBopUur9TFtod56qxbNYzgDkcN5CxUoSFwu83vbqnerH96C7DVhMCGDML_77FV-ix96e3o-WUbGPNprxxB4AiGkGh4H8w_Vjnx6GL_UOFsP0Zg |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CD62L+expression+marks+SARS-CoV-2+memory+B+cell+subset+with+preference+for+neutralizing+epitopes&rft.jtitle=Science+advances&rft.au=Onodera%2C+Taishi&rft.au=Sax%2C+Nicolas&rft.au=Sato%2C+Takashi&rft.au=Adachi%2C+Yu&rft.date=2023-06-16&rft.issn=2375-2548&rft.eissn=2375-2548&rft.volume=9&rft.issue=24&rft_id=info:doi/10.1126%2Fsciadv.adf0661&rft.externalDBID=n%2Fa&rft.externalDocID=10_1126_sciadv_adf0661 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2375-2548&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2375-2548&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2375-2548&client=summon |